↓ Skip to main content

Pioglitazone use and risk of bladder cancer: population based cohort study

Overview of attention for article published in British Medical Journal, March 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
29 news outlets
blogs
3 blogs
twitter
212 X users
facebook
13 Facebook pages
wikipedia
2 Wikipedia pages
googleplus
5 Google+ users

Citations

dimensions_citation
174 Dimensions

Readers on

mendeley
232 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pioglitazone use and risk of bladder cancer: population based cohort study
Published in
British Medical Journal, March 2016
DOI 10.1136/bmj.i1541
Pubmed ID
Authors

Marco Tuccori, Kristian B Filion, Hui Yin, Oriana H Yu, Robert W Platt, Laurent Azoulay

Abstract

 To determine whether pioglitazone compared with other antidiabetic drugs is associated with an increased risk of bladder cancer in people with type 2 diabetes.  Population based cohort study.  General practices contributing data to the United Kingdom Clinical Practice Research Datalink.  A cohort of 145 806 patients newly treated with antidiabetic drugs between 1 January 2000 and 31 July 2013, with follow-up until 31 July 2014.  The use of pioglitazone was treated as a time varying variable, with use lagged by one year for latency purposes. Cox proportional hazards models were used to estimate adjusted hazard ratios with 95% confidence intervals of incident bladder cancer associated with pioglitazone overall and by both cumulative duration of use and cumulative dose. Similar analyses were conducted for rosiglitazone, a thiazolidinedione not previously associated with an increased risk of bladder cancer.  The cohort generated 689 616 person years of follow-up, during which 622 patients were newly diagnosed as having bladder cancer (crude incidence 90.2 per 100 000 person years). Compared with other antidiabetic drugs, pioglitazone was associated with an increased risk of bladder cancer (121.0v88.9 per 100 000 person years; hazard ratio 1.63, 95% confidence interval 1.22 to 2.19). Conversely, rosiglitazone was not associated with an increased risk of bladder cancer (86.2v88.9 per 100 000 person years; 1.10, 0.83 to 1.47). Duration-response and dose-response relations were observed for pioglitazone but not for rosiglitazone.  The results of this large population based study indicate that pioglitazone is associated with an increased risk of bladder cancer. The absence of an association with rosiglitazone suggests that the increased risk is drug specific and not a class effect.

X Demographics

X Demographics

The data shown below were collected from the profiles of 212 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 232 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 232 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 40 17%
Student > Ph. D. Student 34 15%
Student > Master 23 10%
Student > Bachelor 21 9%
Other 19 8%
Other 51 22%
Unknown 44 19%
Readers by discipline Count As %
Medicine and Dentistry 89 38%
Pharmacology, Toxicology and Pharmaceutical Science 26 11%
Biochemistry, Genetics and Molecular Biology 18 8%
Neuroscience 6 3%
Nursing and Health Professions 5 2%
Other 29 13%
Unknown 59 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 379. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2023.
All research outputs
#81,963
of 25,373,627 outputs
Outputs from British Medical Journal
#1,353
of 64,463 outputs
Outputs of similar age
#1,570
of 315,026 outputs
Outputs of similar age from British Medical Journal
#22
of 912 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 64,463 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,026 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 912 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.